inclisiran
-
Alnylam gets $2B funding boost from Blackstone to develop drug pipeline
A key component of the deal includes a $1 billion purchase of 50% of royalties owed to Alnylam on sales of inclisiran, a drug for hypercholesterolemia that works by gene silencing. The company’s CEO said uncertainty and volatility due to Covid-19 meant the timing was right for the deal.
-
Novartis, UK’s NHS form population health partnership around new cholesterol drug
The deal will make the Phase III drug inclisiran – which Novartis acquired when it bought The Medicines Company in November – available to patients in the U.K. and include manufacturing and clinical development efforts.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Novartis wraps up $9.7B Medicines Company buyout
The deal was originally announced in November. The Medicines Co.’s lead product candidate is inclisiran, an RNAi drug for reducing cholesterol, for which it submitted an FDA approval application in December.
-
Novartis to acquire The Medicines Co., maker of cholesterol-lowering drug, for $9.7B
The deal will give the Swiss drugmaker control of inclisiran, a drug for which The Medicines Company plans to file for approval in lipid disorders starting this quarter.
-
The Medicines Co. studies produce further encouraging data on RNAi cholesterol drug
Although it hasn’t yet released details, the company announced positive data from two Phase III studies of inclisiran, which it is developing with Alnylam. The drug prevents production of PCSK9, the target of drugs made by Amgen and Sanofi/Regeneron.
-
MedCo RNA-interference cholesterol drug shows positive Phase III data
Inclisiran, which The Medicines Co. is developing with Alnylam, prevents production of PCSK9, the same protein targeted by two drugs that were the subject of a major patent lawsuit ruling last week. The company plans regulatory filings starting later this year.
-
Amgen drops price of cholesterol-lowering drug Repatha by 60 percent
Equity research analysts wrote in a note Thursday that the move could have a beneficial read-across to another drug that has the same target as Repatha.